EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY-NC-ND 4.0

Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis

Marta Agüera iD, Aleix Soler-Garcia iD, Sara Castellà, Sara Moussalam-Merino, Carme Alejandre, Daniel Penela-Sánchez iD, Cristina Esteva, Clàudia Fortuny, Mariona Fernández de Sevilla iD, Juan-José García-García iD, Iolanda Jordan iD, Carmen Muñoz-Almagro iD and 1 more

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71873 ↗

At a glance

Beobachtungsstudie in Pediatric Pulmonology, 2026. Written by Marta Agüera and 12 co-authors. Institution: Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain. Major MEDLINE topics: Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Bronchiolitis, Bronchiolitis, Viral. 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AGAUR, Agència de Gestió d'Ajuts Universitaris i de Recerca.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Nirsevimab was approved in Europe in 2022 for respiratory syncytial virus (RSV) prevention. In October 2023, Catalonia (Spain) launched a universal immunization program for infants under 6 months during their first RSV season. This study aims to assess the characteristics of patients admitted with bronchiolitis following nirsevimab implementation and to compare the features of the immunized patients across two consecutive seasons.

Methods

This prospective, observational, single‐center study included infants aged up to 12 months admitted for bronchiolitis between October 2023 and May 2025, comparing clinical and epidemiological data across two seasons (S1: October 2023–May 2024; S2: October 2024–May 2025).

Results

574 patients were included (S1: 352; S2: 222), with a median age of 3.2 months (interquartile range [IQR]: 1.5–6.5). Most were previously healthy (437/574, 76.1%) and immunized with nirsevimab (406/574, 70.7%). RSV was detected in 215/574 (37.5%) of cases. 159/574 (27.7%) required Pediatric Intensive Care Unit (PICU) admission, and the median length of hospital stay was 5 days (IQR:3–8). In S2, immunization rates increased (S1:61.6% vs S2:85.1%, p = < 0.001) whereas RSV infections decreased (S1:41.2% vs S2: 31.5%, p = 0.020). Among immunized patients, S2 exhibited a higher proportion of healthy children (S1:65.0% vs S2:77.8%, p = 0.005), fewer PICU admissions (S1:33.2% vs S2:21.2%, p = 0.007) and shorter hospital stays (S1: 6 [IQR:4–9.5] days vs S2: 5 [IQR:3–7.5] days, p = 0.033). Furthermore, in multivariable logistic regression analysis, admission during the second season remained independently associated with a lower risk of PICU admission (adjusted OR 0.587, 95% CI 0.368–0.936; p = 0.025).

Conclusion

Among hospitalized infants with bronchiolitis after nirsevimab implementation, immunized patients admitted during the second season showed more favorable clinical outcomes, including lower PICU utilization and shorter hospitalizations.

Subjects

MeSH terms (MEDLINE)

Respiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedBronchiolitisBronchiolitis, ViralAntiviral AgentsHumansInfantProspective StudiesMaleFemaleSpainHospitalizationRespiratory Syncytial Virus, HumanSeasonsLength of Stay

Author keywords

bronchiolitisimmunisation programmenirsevimabrespiratory syncytial virus

Substances

Antibodies, Monoclonal, HumanizedAntiviral Agents

Authors and institutions

  • Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain.
  • PhD Candidate, PhD Program in Medicine and Translational Research, Universitat de Barcelona, Barcelona, Spain.
  • Pediatric Infectious Diseases and Microbiome Research Group, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
  • Departament de Cirurgia i Especialitats Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
  • CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Pediatric Intensive Care Unit Department, Hospital Sant Joan de Déu, Barcelona, Spain.

ORCID profiles: Marta Agüera, Aleix Soler-Garcia, Daniel Penela-Sánchez, Mariona Fernández de Sevilla, Juan-José García-García, Iolanda Jordan, Carmen Muñoz-Almagro, Cristian Launes

Funding

  • AGAUR
  • Agència de Gestió d'Ajuts Universitaris i de Recerca

Cite

APA

Agüera, M., Soler-Garcia, A., Castellà, S., Moussalam-Merino, S., Alejandre, C., Penela-Sánchez, D., Esteva, C., Fortuny, C., Fernández de Sevilla, M., García-García, J. J., Jordan, I., Muñoz-Almagro, C., & Launes, C. (2026). Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71873

Vancouver

Agüera M, Soler-Garcia A, Castellà S, Moussalam-Merino S, Alejandre C, Penela-Sánchez D, et al. Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71873

BibTeX
@article{Agera2026,
  author = {Agüera, Marta and Soler-Garcia, Aleix and Castellà, Sara and Moussalam-Merino, Sara and Alejandre, Carme and Penela-Sánchez, Daniel and Esteva, Cristina and Fortuny, Clàudia and Fernández de Sevilla, Mariona and García-García, Juan-José and Jordan, Iolanda and Muñoz-Almagro, Carmen and Launes, Cristian},
  title = {Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71873}
}
Start for free →